KTTA Latest Press Releases

-- June 16, 2026 --

Pasithea Therapeutics Announces Amendments to Clinical Study Protocol for Phase 1/1B NF1 Clinical Trial Globe Newswire 7:00 AM

-- June 15, 2026 --

Pasithea Therapeutics Announces Exhibit at Children's Tumor Foundation 2026 NF Conference Globe Newswire 7:02 AM

-- June 2, 2026 --

Pasithea Therapeutics Announces Orphan Drug Designation by FDA of PAS-004 for Treatment of Amyotrophic Lateral Sclerosis (ALS) Globe Newswire 7:02 AM

-- May 4, 2026 --

Pasithea Therapeutics Announces Appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical Officer Globe Newswire 7:01 AM

-- April 20, 2026 --

Pasithea Therapeutics Announces Grant of Rare Pediatric Disease Designation (RPDD) by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Globe Newswire 7:01 AM

-- April 1, 2026 --

Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Causing Significant Morbidity Globe Newswire 7:01 AM

-- February 17, 2026 --

Pasithea Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference Globe Newswire 7:01 AM

Market Data Delayed 15 Minutes

Questions? Feedback?Olark live chat software